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Virology in the Next Millennium Minireview
achievements led to the eradication of viral diseasesMichael B. A. Oldstone, M.D.,*
and Arnold J. Levine, Ph.D.² that had killed over 400 million people in the twentieth
*The Scripps Research Institute century alone, over 4-fold more than were killed by all
La Jolla, California 92037 the wars of this century (Oldstone, 1998). An estimated
²The Rockefeller Institute 12% to 20% of human cancers are caused by viruses
New York, New York 10021 (Zur Hausen, 1991; Gallo et al., 1999), and so the strategy
utilized to prevent liver cancer caused by HBV will surely
be applied to other cancers in the twenty-first century.
Viruses were first inferred to exist by the diseases they Over the past 40 years viruses have played a central
caused. Although disease manifestations like rabies, role in our present-day understanding of DNA structure
paralytic poliomyelitis, smallpox, and measles were and genomes, transcriptional signals (enhancers, pro-
noted in antiquity, viruses as infectious agents were moters), the transcriptional machinery and transcription
defined just over 100 years ago. Their discovery was factors, RNA processing, splicing, poly A±addition, RNA
made initially possible by the revolution in microbiology transport, protein localization in cells, and protein pro-
led by Louis Pasteur and refined in concept by Robert cessing. The oncogenes and tumor suppressor genes
Koch and Joseph Lister at the last half of the nineteenth were first uncovered using viruses. Viruses have been
century. These and other scientists discovered that mi- excellent probes into the mysteries of the cells and the
croscopic organisms produced disease and the pres- host animal. Genetic manipulation of both the virus and
ence of the microbe could be defined by several criteria host are defining the molecular basis of viral diseases
such as their retention on a Pasteur±Chamberlain filter, (Oldstone, 1996).
visualization by light microscopy, and growth on agars But what does the future hold for virology as the mil-
and in broths. However, a subset of diseases failed these lennium ends and the next one begins? First we need
experimental tests and a new class of organisms were to appreciate that the demographics of human popula-
uncovered. Specifically, independent observations by tions in the twenty-first century are changing in ways
Ivanovsky (1892, 1899) and by Beijerinck (1898) with a that will impact viruses that prey upon humans. In the
disease of tobacco leaves, and by Loeffler and Frosch next century the rate of population growth will slow, but
(1898) with foot-and-mouth disease of cattle, demon- we will increase our numbers from six billion (in 2000
strated an infectious agent that passed through the por- AD) to eight to ten billion by 2050 AD. In the twenty-first
celain filter to the bottom of the flask, was not visible century we will become a predominantly urban species.
by light microscopy, and failed to grow in agar/broth Today 47 percent of people live in cities; in 2050 AD the
cultures (Table 1). Indeed it was not until 40 years later, great majority of people will live in cities populated with
in the 1930s (Kausche et al., 1939), that tobacco mosaic greater than 10 million people (today there are 20 such
virus was observed by electron microscopy and nearly cities worldwide). We will be more dependent upon our
50 years before poliovirus could be reproducibly grown technologies to manage the potential for emerging viral
in tissue culture cells (Enders et al., 1954). The ability infections.
to grow viruses in cultured cells was the technological In the twenty-first century, many countries will have
breakthrough that freed virologists from the need to for the first time in history three times more people over
passage viruses in animals (Gard, 1954) and allowed the age of 60 years than under the age of 4 years. Be-
sufficient recovery of viruses to allow the birth and devel- cause of this, influenza epidemics could be the most
opment of biochemical virology in the 1960s and its
important emerging and evolving virus. Few people in
expansion to the molecular biology of viruses in the
the year 2050 AD will have been immunized for smallpox,
1970s±1980s.
a disease eradicated in the twentieth century. Is thereWith sufficient amounts of virus on hand, viral struc-
any possibility it or a relative could return? The humanture, function, and genomic organization followed, lead-
immunodeficiency virus and hepatitis C virus will surelying to insights in replication, transcription, translation,
require novel approaches in the next century if we are tolatency, and integration and the beginning of our under-
control these infections. The human immunodeficiencystanding of how virus transformed cells to a cancerous
virus has caused a downturn in the population with astate or how viruses persisted in animals. Because vi-
lessening of the mean expectation of life (in Africa) forruses are small units of packaged genes and cis-acting
the first time since the 1918/1919 influenza pandemic.signals ranging in size from a few hundred bases (vi-
While HIV and hepatitis C viruses have already spreadroids) to agents with 300 genes, viruses became useful
throughout the world, the hemorrhagic fever virusesinstruments for the study of genetics, cell biology, struc-
(ebola, dengue) and hantaan viruses appear to wait intural biology, and biochemistry, allowing the study of
the wings before widespread diseases appear. Animalmany basic parameters of life and development. In addi-
viruses such as African swine fever virus are on thetion, cell culture permitted the development of large-
move; from Africa to Portugal in 1957, to Spain in 1960scale production of vaccines to prevent, for example,
and the Caribbean and South America by the late 1960sparalytic poliomyelitis (the first vaccine produced in cell
and early 1970s. New viruses are continuously beingculture), measles, congenital abnormalities caused by
uncovered although for several their role in disease isrubella, and most recently the prevention of cancer re-
sulting from hepatitis B virus chronic infections. These still undetermined.
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Table 1. Selected Milestones in Virology
Date(s) Virologist(s)(References) Discovery
1892,1898 D.I. Ivanofsky, M. Beijerinck(1±3) First demonstrations of a filterable plant virus: tobacco
mosaic virus.
1898 F. Loeffler & P. Frosch(4) First demonstration of a filterable animal virus: foot-and-
mouth disease virus.
1901 W. Reed et al. (U.S. Army Yellow Fever First human virus: yellow fever virus.
Commission)(5,6) First use of consent form for human clinical investigation.
1904±1908 V. Ellermann & O. Bang, H. Vallee & First demonstration of a leukemia-causing virus, retrovirus.
H. Carre(7,8)
1908 C. von Pirquet(9) First report of virus causing immunosuppression: measles
virus.
1909 K. Landsteiner & E. Popper(10,11) Isolation of poliomyelitis virus.
1911 P. Rous(12) First demonstration of a solid tumor virus: Rous sarcoma
virus.
1915 F. Twort(13) Discovery of bacteriophages.
1917 F. d'Herelle(14) Bacteriophages, plaque assay.
1923±1928 A. Carrel, H. Maitland & M. Maitland(15,16) Tissue culture of embryo explants and first tissue culture
cultivation of virus: Rous virus, vaccinia virus.
1931 J. Furth(17) Use of mice as a host for viruses.
1931 A. Woodruff & E. Goodpasteur(18) Use of embryonated hen's eggs as a host for viruses.
1933 W. Smith, C.H. Andrews & P.P. Laidlow(19) Isolation of human influenza virus.
1933 R. Shope(20) Rabbit papilloma virus: first DNA tumor virus.
1936 P. Rous, J. Beard(21) Rabbit papilloma virus induces carcinomas in a different
species.
1939 G. Kausche, P. Ankuch, H. Ruska(22) First electron micrograph of a virus: tobacco mosaic virus.
1946 W. Stanley, J. Summer, J. Northrop(23,24) Preparation of a viral protein in a pure form: tobacco mosaic
virus.
1948±1955 J. Enders, F. Robbins, T. Weller(25±27) Routine use of tissue culture to grow and study viruses.
H. Eagle(28) Development of optimal media for growing cells.
1937±1951 M. Theiler, H. Smith(29,30) Development of 17D strain human yellow fever vaccine:
made in animal and embryonic cultures.
1954±1961 J. Salk, A. Sabin, H. Koprowski, J. Enders, Development of poliomyelitis virus vaccine. Development
S. Katz, S. Krugman(31±34) of measles virus vaccine: made in tissue culture.
1957 A. Isaacs, J. Lindenmann(35,36) Discovery of interferon.
1950±1970s S. Luria, M. DelbruÈ ck, J. Monod, Quantitative plaque assay, origins of molecular biology and
E. Wollman, A. Hershey, S. Benzer, molecular virology.
S. Cohen, D. Nathans, R. Dulbecco,
D. Baltimore, H. Smith, W. Arber,
H. Temin, P. Sharp(37±48)
1950, 1960, B. Sigurdsson, B. Blumberg, C. Gajdusek, Persistent, latent, and slow virus infections. Prions.
1980s S. Prusiner, J. Stevens et al.(49±54)
1954 W. Rowe(55) Role of thymus in immune responses to virus.
1970s±1980s R. Zinkernagel & P. Doherty, M. Oldstone, Major histocompatibility restriction and cytotoxic T
B. Fields, B. Moss et al.(56) lymphocytes, immune mediated viral diseases,
molecular pathogenesis.
1969±1976 R. Heubner, P. Vogt, M. Bishop, H. Varmus Oncogenes.
et al.(57,58)
1977 World Health OrganizationÐMany health Eradication of smallpox as a disease that killed over 300
workers and virologists(59) million people in the twentieth century.
1978±1985 S. Harrison, A. Olson, J. Hogle, First atomic structure of a plant (tomato bush stunt) and
M. Rossman, R. Rueckert(60±62) animal (poliomyelitis, rhinovirus) virus.
1979 D. Lane, L. Crawford, D. Linzer, SV40T-antigen-p53, virus host cell interaction-tumor
A. Levine(63,64) suppressors.
1981 J. Skehel, D. Wiley, I. Wilson et al.(65) Structure/function of influenza virus hemagglutinin. First
atomic structure of a glycoprotein.
1981±1984 R. Gallo, F. BarreÂ -Sinoussi, L. Montagnier, First human retrovirus.
Y. Hinuma(66±71)
1984±20001 M. Hilleman et al.(72) First molecular recombinant virus vaccine: hepatitis B virus.
First vaccine to successfully treat cancer: hepatitis B
virus-induced liver cancer.
2000±2015 World Health OrganizationÐMany health Planned eradication/elimination of poliomyelitis virus (by
workers and virologists 2002 to 2005) and measles virus (by 2015) as a
disease.
How are we going to respond? The World Health Orga- century will prevent expected liver cancers in the Far
East. New disciplines will be developed to respond tonization predicts the worldwide eradication of poliovirus
by the end of the first decade of the next century. Mea- these challenges. Viral diagnoses in the field (PCR, large
volume DNA sequencing) will develop a new fieldsles is anticipated to be eliminated by 2015 AD. Shortly
thereafter, the hepatitis B vaccinations of the twentieth of molecular epidemiology, which could be rapidly
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translated to new modes of vaccine development and laboratories. How does herpevirus latency in neurons
or lymphoid cells occur and what are the events in reacti-novel methods of immunization using dendritic cells or
cytokines to enhance responses to antigens. Renewed vation of these viruses? How do viruses persist or main-
tain chronic active infections in their host? What newefforts in viral drug development will produce novel
drugs that selectively control or eliminate some viruses. diseases do they cause? How do the cancer viruses
cause a tumor to arise? We need to understand changesTechnology of DNA assays and informatics will provide
a molecular understanding of virus±host cell responses in viral evolution, altered host range specificity, the
causes of virulence and attenuation via mutations, andboth in vitro and in vivo.
The field of gene therapy, which has promised a great the control of mutation rate in viruses. The RNA viruses
are unique and live on the edge of their ªerror thresholdº,deal, but only produced limited successes in the twenti-
eth century, will depend upon the development of virus which means that their mutation rates and their rate of
evolution will be a big problem in our future. Viruses ofvectors in the twenty-first century. Recombinant and
mutant viruses will be used in vaccines, in gene replace- our evolutionary past (retroviruses) may comprise 1%±
10% of our genome. Did they play a role in our evolutionment therapy, and for the selective killing of tumor cells
in people. Viral agents that cause old diseases will be and have we overlooked their role in disease? What is
their impact upon our diversity, immune response, oruncovered, perhaps for type I diabetes, multiple sclero-
sis, or other neurological syndromes. Viruses that have response to other viruses?
Finally, viruses will continue to be the tools in ourevolved a way to enhance or inhibit inflammatory reac-
tions, immunosuppress the host, or evade an immune ever-expanding revolution in the biological sciences.
Basic science laboratories will continue to utilize viralresponse will be characterized and understood. These
very viral genes and approaches will then be applied to genes and enzymes, viral promoters, viral proteins,
and viral capsids to explore the fundamental questionsrelieve autoimmune diseases in humans.
But surely viruses will continue to lead the way in of life processes. The twenty-first century will provide
new challenges both to the viruses and to the virolo-the basic sciences, as well as in clinical sciences.
Great questions remain in virology and its research gists.
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